Sweden launches major trial pitting two immunotherapy approaches for melanoma

Swedish researchers are testing whether combining two checkpoint inhibitors beats single-drug treatment for advanced melanoma surgery candidates. The phase III trial could reshape treatment protocols across Europe and influence how oncologists approach pre-surgical immunotherapy — a decision with major implications for drug manufacturers and healthcare budgets.

Originaltitel: SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial